<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Med</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1076-1551</issn>
<issn pub-type="epub">1528-3658</issn>
<publisher>
<publisher-name>Feinstein Institute for Medical Research</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27385396</article-id>
<article-id pub-id-type="pmc">5082295</article-id>
<article-id pub-id-type="doi">10.2119/molmed.2016.00122</article-id>
<article-id pub-id-type="publisher-id">2016.00122</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Altered Redox Mitochondrial Biology in the Neurodegenerative Disorder Fragile X-Tremor/Ataxia Syndrome: Use of Antioxidants in Precision Medicine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>Gyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="author-notes" rid="cor1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Napoli</surname>
<given-names>Eleonora</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="author-notes" rid="cor1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wong</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Siming</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giulivi</surname>
<given-names>Cecilia</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<aff id="aff1"><label>1</label>Department of Molecular Biosciences, School of Veterinary Medicine, Davis, California, United States of America;</aff>
<aff id="aff2"><label>2</label>Medical Investigations of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, California, United States of America;</aff>
<aff id="aff3"><label>3</label>Department of Pediatrics, University of California Davis Medical Center, Sacramento, California, United States of America;</aff>
<aff id="aff4"><label>4</label>Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, California, United States of America</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>#</label>GS and EN contributed equally to this work.</corresp>
<corresp id="cor2">Address correspondence to Cecilia Giulivi, University of California, Department of Molecular Biosciences, 3009 Vet Med 3B, 1089 Veterinary Medicine Dr., Davis, CA 95616, USA. Phone: +1-530-754 8603; Fax: +1-530-754 9342; E-mail: <email>cgiulivi@ucdavis.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p>
<bold>DISCLOSURE</bold>
</p>
<p>RH has received funding from Novartis, Roche/Genentech, Alcobra and Neuren for treatment trials in fragile X syndrome, autism and Down syndrome. She has also consulted with Novartis, Roche/Genentech and Zynerba regarding treatment for fragile X syndrome.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>6</month>
<year>2016</year>
</pub-date>
<volume>22</volume>
<fpage>548</fpage>
<lpage>559</lpage>
<history>
<date date-type="received">
<day>06</day>
<month>5</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>6</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2016 The Feinstein Institute for Medical Research</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="mol-22-16_122_Song.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<p>A 55–200 expansion of the CGG nucleotide repeat in the 5’-UTR of the fragile X mental retardation 1 gene (<italic>FMR1</italic>) is the hallmark of the triplet nucleotide disease known as the “premutation” as opposed to those with &gt;200 repeats, known as the full mutation or fragile X syndrome. Originally, premutation carriers were thought to be free of phenotypic traits; however, some are diagnosed with emotional and neurocognitive issues and, later in life, with the neurodegenerative disease fragile X-associated tremor/ataxia syndrome (FXTAS). Considering that mitochondrial dysfunction has been observed in fibroblasts and post-mortem brain samples from carriers of the premutation, we hypothesized that mitochondrial dysfunction-derived reactive oxygen species (ROS) may result in cumulative oxidative-nitrative damage. Fibroblasts from premutation carriers (<italic>n</italic> = 31, all FXTAS-free except 8), compared with age- and sex-matched controls (<italic>n</italic> = 25), showed increased mitochondrial ROS production, impaired Complex I activity, lower expression of MIA40 (rate-limiting step of the redox-regulated mitochondrial-disulfide-relay-system), increased mtDNA deletions and increased biomarkers of lipid and protein oxidative-nitrative damage. Most of the outcomes were more pronounced in FXTAS-affected individuals. Significant recovery of mitochondrial mass and/or function was obtained with superoxide or hydroxyl radicals’ scavengers, a glutathione peroxidase analog, or by overexpressing MIA40. The effects of ethanol (a hydroxyl radical scavenger) were deleterious, while others (by <italic>N</italic>-acetyl-cysteine, quercetin and epigallocatechin-3-gallate) were outcome- and/or carrier- specific. The use of antioxidants in the context of precision medicine is discussed with the goal of improving mitochondrial function in carriers with the potential of decreasing the morbidity and/or delaying FXTAS onset.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>